IN2015DN03206A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03206A
IN2015DN03206A IN3206DEN2015A IN2015DN03206A IN 2015DN03206 A IN2015DN03206 A IN 2015DN03206A IN 3206DEN2015 A IN3206DEN2015 A IN 3206DEN2015A IN 2015DN03206 A IN2015DN03206 A IN 2015DN03206A
Authority
IN
India
Prior art keywords
nucleic acid
acid sequence
present
vector
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Sondermann
Meer Dominik Ter
Thomas Pohl
Reno Winter
Uwe Jacob
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of IN2015DN03206A publication Critical patent/IN2015DN03206A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
IN3206DEN2015 2012-10-30 2013-10-30 IN2015DN03206A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Publications (1)

Publication Number Publication Date
IN2015DN03206A true IN2015DN03206A (zh) 2015-10-02

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3206DEN2015 IN2015DN03206A (zh) 2012-10-30 2013-10-30

Country Status (28)

Country Link
US (1) US10028998B2 (zh)
EP (1) EP2914624B1 (zh)
JP (2) JP6423351B2 (zh)
KR (1) KR102170674B1 (zh)
CN (1) CN104918955B (zh)
AU (1) AU2013340831B2 (zh)
BR (1) BR112015008815A2 (zh)
CA (1) CA2887164C (zh)
CL (1) CL2015001127A1 (zh)
DK (1) DK2914624T3 (zh)
EA (1) EA033437B9 (zh)
ES (1) ES2628049T3 (zh)
HK (1) HK1209765A1 (zh)
HR (1) HRP20170894T1 (zh)
HU (1) HUE032786T2 (zh)
IL (1) IL238528A (zh)
IN (1) IN2015DN03206A (zh)
LT (1) LT2914624T (zh)
MX (1) MX359802B (zh)
MY (1) MY173686A (zh)
NZ (1) NZ706884A (zh)
PH (1) PH12015500771B1 (zh)
PL (1) PL2914624T3 (zh)
PT (1) PT2914624T (zh)
RS (1) RS56075B1 (zh)
SG (1) SG11201502749VA (zh)
SI (1) SI2914624T1 (zh)
WO (1) WO2014068012A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CA2927263C (en) 2013-10-16 2022-12-13 Suppremol Gmbh Soluble fc gamma receptor for treatment of autoimmune bullous diseases
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えＦｃγＲＩＩｂ
CN112423900A (zh) * 2018-06-25 2021-02-26 巴斯夫涂料有限公司 生产优化涂层的方法和使用所述方法可获得的涂层
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2547126C (en) 2003-11-26 2014-07-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human igg fc receptor iib (fcyriib)
PL1960427T3 (pl) 2005-12-13 2011-07-29 Suppremol Gmbh Multimeryczne polipeptydy receptora Fc
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Also Published As

Publication number Publication date
KR20150122621A (ko) 2015-11-02
JP2016503289A (ja) 2016-02-04
PT2914624T (pt) 2017-06-07
IL238528A0 (en) 2015-06-30
PL2914624T3 (pl) 2017-09-29
NZ706884A (en) 2019-05-31
BR112015008815A2 (pt) 2017-11-21
MY173686A (en) 2020-02-15
AU2013340831A1 (en) 2015-04-30
RS56075B1 (sr) 2017-10-31
LT2914624T (lt) 2017-06-26
SI2914624T1 (sl) 2017-07-31
DK2914624T3 (en) 2017-06-26
EA033437B1 (ru) 2019-10-31
IL238528A (en) 2017-07-31
JP2018186833A (ja) 2018-11-29
HRP20170894T1 (hr) 2017-09-08
KR102170674B1 (ko) 2020-10-28
EA033437B9 (ru) 2020-03-19
CA2887164C (en) 2020-12-29
MX359802B (es) 2018-10-10
PH12015500771A1 (en) 2015-06-08
HK1209765A1 (zh) 2016-04-08
MX2015005266A (es) 2015-10-26
EP2914624B1 (en) 2017-03-15
AU2013340831B2 (en) 2017-11-23
JP6423351B2 (ja) 2018-11-14
CN104918955B (zh) 2018-10-09
CL2015001127A1 (es) 2015-12-18
HUE032786T2 (en) 2017-10-30
CN104918955A (zh) 2015-09-16
WO2014068012A1 (en) 2014-05-08
EA201590845A1 (ru) 2015-08-31
ES2628049T3 (es) 2017-08-01
CA2887164A1 (en) 2014-05-08
SG11201502749VA (en) 2015-05-28
US10028998B2 (en) 2018-07-24
EP2914624A1 (en) 2015-09-09
US20140120080A1 (en) 2014-05-01
PH12015500771B1 (en) 2015-06-08

Similar Documents

Publication Publication Date Title
IN2015DN03206A (zh)
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
IN2014CN04586A (zh)
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX337985B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX351565B (es) Colageno 7 y metodos relacionados.
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
EP4223772A3 (en) Optimized factor viii gene
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
MX2013004892A (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX369726B (es) Polipéptidos con actividad proteasa.
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
EP3929285A3 (en) Methods of reducing odor
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2012136898A3 (en) Novel cutinases, their production and uses
MX350391B (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
MX363360B (es) Polipéptidos que poseen actividad proteasa y polinucleótidos que los codifican.
WO2012030858A3 (en) Polypeptides having hemicellulolytic activity and polynucleotides encoding same
WO2013079531A3 (en) Polypeptides having peroxygenase activity and polynucleotides encoding same
WO2013021063A3 (en) Polypeptides having peroxygenase activity and polynucleotides encoding same